Literature DB >> 33800158

Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake.

Matteo Bauckneht1,2, Silvia Morbelli1,2, Alberto Miceli2, Sara Elena Rebuzzi3,4, Giuseppe Fornarini3.   

Abstract

Neuroendocrine differentiation (NED) of prostate cancer represents an acknowledged predictor of resistant and more aggressive disease. NED can be functionally exploited in vivo using PET/CT imaging with somatostatin analogs radiolabeled with 68Ga. Many previous reports have shown that 18F-FDG PET/CT should also be used in cases such as guiding management, as NED is systematically associated with increased glycolysis. We hereby discuss the case of a metastatic prostate cancer patient in which 68Ga-Dotatoc PET/CT revealed the occurrence of NED with low FDG-avidity.

Entities:  

Keywords:  18F-Fluorodeoxyglucose; 68Ga-Dotatoc; metastatic castration-resistant prostate cancer; neuroendocrine differentiation; positron emission tomography

Year:  2021        PMID： 33800158      PMCID： PMC7998830          DOI： 10.3390/diagnostics11030468

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN： 2075-4418


  19 in total

1.  Survival of patients with small cell carcinoma of the prostate during 1973-2003: a population-based study.

Authors:  Sundeep Deorah; Marepalli B Rao; Rachna Raman; Krishnanath Gaitonde; James F Donovan
Journal:  BJU Int       Date:  2011-08-23       Impact factor: 5.588

2.  Lu177-PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution.

Authors:  Rhiannon McBean; Brooke O'Kane; Rex Parsons; David Wong
Journal:  J Med Imaging Radiat Oncol       Date:  2019-04-25       Impact factor: 1.735

3.  18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.

Authors:  Emine Acar; Gamze Çapa Kaya
Journal:  Clin Nucl Med       Date:  2019-01       Impact factor: 7.794

4.  Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.

Authors:  Min Zou; Roxanne Toivanen; Antonina Mitrofanova; Nicolas Floch; Sheida Hayati; Yanping Sun; Clémentine Le Magnen; Daniel Chester; Elahe A Mostaghel; Andrea Califano; Mark A Rubin; Michael M Shen; Cory Abate-Shen
Journal:  Cancer Discov       Date:  2017-04-14       Impact factor: 39.397

5.  The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma.

Authors:  Wei Li; Alexa Cohen; Yin Sun; Jill Squires; Daniel Braas; Thomas G Graeber; Lin Du; Gang Li; Zhen Li; Xiang Xu; Xufeng Chen; Jiaoti Huang
Journal:  Mol Cancer Res       Date:  2016-02-01       Impact factor: 5.852

6.  Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.

Authors:  Hossein Jadvar; Bhushan Desai; Lingyun Ji; Peter S Conti; Tanya B Dorff; Susan G Groshen; Jacek K Pinski; David I Quinn
Journal:  J Nucl Med       Date:  2013-06-19       Impact factor: 10.057

7.  Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for 18F-FDG Imaging of PSMA-Suppressed Tumors.

Authors:  Martin K Bakht; Jessica M Lovnicki; Janice Tubman; Keith F Stringer; Jonathan Chiaramonte; Michael R Reynolds; Iulian Derecichei; Rosa-Maria Ferraiuolo; Bre-Anne Fifield; Dorota Lubanska; So Won Oh; Gi Jeong Cheon; Cheol Kwak; Chang Wook Jeong; Keon Wook Kang; John F Trant; Colm Morrissey; Ilsa M Coleman; Yuzhuo Wang; Hojjat Ahmadzadehfar; Xuesen Dong; Lisa A Porter
Journal:  J Nucl Med       Date:  2019-12-05       Impact factor: 11.082

Review 8.  Neuroendocrine and Aggressive-Variant Prostate Cancer.

Authors:  Nicholas Spetsieris; Myrto Boukovala; Georgios Patsakis; Ioannis Alafis; Eleni Efstathiou
Journal:  Cancers (Basel)       Date:  2020-12-16       Impact factor: 6.639

9.  Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer.

Authors:  Stephen Yiu Chuen Choi; Susan L Ettinger; Dong Lin; Hui Xue; Xinpei Ci; Noushin Nabavi; Robert H Bell; Fan Mo; Peter W Gout; Neil E Fleshner; Martin E Gleave; Colin C Collins; Yuzhuo Wang
Journal:  Cancer Med       Date:  2018-06-14       Impact factor: 4.452

Review 10.  Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play.

Authors:  Girijesh Kumar Patel; Natasha Chugh; Manisha Tripathi
Journal:  Cancers (Basel)       Date:  2019-09-20       Impact factor: 6.639
View more
  1 in total

Review 1.  Beyond the Prognostic Value of 2-[18F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management.

Authors:  Roberto Borea; Diletta Favero; Alberto Miceli; Maria Isabella Donegani; Stefano Raffa; Annalice Gandini; Malvina Cremante; Cecilia Marini; Gianmario Sambuceti; Elisa Zanardi; Silvia Morbelli; Giuseppe Fornarini; Sara Elena Rebuzzi; Matteo Bauckneht
Journal:  Diagnostics (Basel)       Date:  2022-02-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.